Beta Bionics (NASDAQ:BBNX) Stock Rating Upgraded by Wall Street Zen

Beta Bionics (NASDAQ:BBNX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other research analysts have also commented on BBNX. Bank of America upped their price target on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, September 15th. William Blair started coverage on Beta Bionics in a research report on Friday, August 21st. They issued a “market perform” rating on the stock. Truist Financial reissued a “buy” rating and set a $23.00 target price (up from $22.00) on shares of Beta Bionics in a research note on Tuesday, September 15th. UBS Group restated a “buy” rating and set a $25.00 target price on shares of Beta Bionics in a report on Tuesday, September 15th. Finally, Robert W. Baird raised their price target on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.90.

Beta Bionics Stock Performance

BBNX stock opened at $21.89 on Friday. The firm’s 50-day moving average price is $17.66 and its two-hundred day moving average price is $14.06. Beta Bionics has a 12-month low of $8.80 and a 12-month high of $32.71. The stock has a market capitalization of $984.83 million, a price-to-earnings ratio of -13.27 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Equities analysts predict that Beta Bionics will post -2.06 EPS for the current year.

Insider Activity at Beta Bionics

In other Beta Bionics news, insider Steven Russell sold 4,221 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $80,663.31. Following the transaction, the insider owned 169,628 shares in the company, valued at approximately $3,241,591.08. This represents a 2.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 36,870 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total value of $680,620.20. Following the completion of the transaction, the insider directly owned 87,157 shares of the company’s stock, valued at $1,608,918.22. This represents a 29.73% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 103,561 shares of company stock valued at $1,962,504 in the last three months. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Eventide Asset Management LLC lifted its position in Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock valued at $152,233,000 after buying an additional 37,476 shares during the period. BlackRock Inc. bought a new stake in shares of Beta Bionics during the 2nd quarter valued at $52,340,000. Eversept Partners LP grew its position in shares of Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after buying an additional 736,576 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Beta Bionics in the 4th quarter worth about $40,437,000. Finally, Perceptive Advisors LLC increased its stake in shares of Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after acquiring an additional 240,000 shares in the last quarter.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding its diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, potentially giving the company a second growth platform. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Beta Bionics closed a public offering that generated $172.5 million in gross proceeds, including full exercise of the underwriters’ option. The capital should support Mint’s commercialization, manufacturing, research and development, and working capital needs. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Positive Sentiment: Analyst sentiment remains broadly favorable. Recent price-target increases and a reported “Moderate Buy” consensus reflect optimism surrounding Mint and longer-term demand for automated insulin-delivery systems.
• Neutral Sentiment: Insiders Mark Hopman and Mike Mensinger sold shares under pre-arranged Rule 10b5-1 plans. The transactions totaled roughly $678,000 and do not necessarily indicate a change in management’s outlook, though they may affect sentiment. Beta Bionics Insider Trading
• Negative Sentiment: The equity offering issued millions of shares and pre-funded warrants at $17.25, creating dilution for existing shareholders and potentially limiting near-term upside.
• Negative Sentiment: Multiple law firms publicized a securities class action alleging inadequate disclosure of FDA Form 483 and warning-letter issues, including quality-management, patient-safety and customer-complaint concerns. The allegations remain unproven, but the litigation creates regulatory, reputational and financial uncertainty; the lead-plaintiff deadline is November 3, 2026. BBNX Securities Class Action Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the approximately $133.9 million analyst consensus, signaling weaker near-term growth expectations.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.